Investor Alert: MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud

Levi & Korsinsky, LLP, a well-known law firm specializing in securities litigation, has announced a class action lawsuit against MoonLake Immunotherapeutics, identified publicly as MLTX, on November 14, 2025. The lawsuit is geared towards recovering financial losses incurred by investors due to alleged securities fraud during a specified timeframe from March 10, 2024, to September 29, 2025.

Case Overview

The class action aims to protect those who purchased shares of MoonLake Immunotherapeutics, particularly in the wake of false statements and misleading information regarding the company’s drug candidates. The complaint outlines serious allegations, stating that the company misrepresented critical aspects of its main drug candidate, SLK, and its comparison to BIMZELX, another medicinal product that targets similar molecular pathways.

According to the lawsuit, the defendants are accused of:
1. Concealing the fact that both SLK and BIMZELX target the same inflammatory cytokines, IL-17A and IL-17F;
2. Making claims about SLK’s unique Nanobody structure that misled investors regarding its clinical benefits over BIMZELX;
3. Misrepresenting SLK’s tissue penetration capabilities as they did not result in the expected clinical efficacy;
4. Lacking a reasonable basis for asserting SLK’s superiority over traditional monoclonal antibodies.

Next Steps for Investors

For those who believe they have a stake in the case, there is a limited window to take action. Interested parties are encouraged to contact legal representation from Levi & Korsinsky by December 15, 2025, to discuss appointments as lead plaintiffs. Notably, to qualify for any eventual compensation from the case, individuals do not need to serve as lead plaintiffs to be included in the benefits of the lawsuit.

Cost of Participation

Levi & Korsinsky assures potential participants that there will be no costs or obligations required from class members. The firm offers the potential for affected shareholders to gain monetary benefits without any upfront fees or out-of-pocket expenses. This no-cost approach aims to ensure participation from all eligible investors.

Why Choose Levi & Korsinsky?

Having accumulated more than two decades of experience in securities law, Levi & Korsinsky boasts a proven record in securing substantial settlements for their clients. The firm’s successful history encompasses hundreds of millions in recovery for it shareholders and includes high-stake litigations across various industries. For seven consecutive years, it has been acknowledged in ISS Securities Class Action Services' Top 50 Report for its excellence in this field.

Contact Information

For further details about the lawsuit, investors may reach out to Joseph E. Levi, Esq. or Ed Korsinsky, Esq., both of whom are leading the case, via:

- Email: [email protected]
- Phone: (212) 363-7500
- Office Address: 33 Whitehall Street, 27th Floor, New York, NY 10004

In conclusion, this lawsuit presents a critical opportunity for MoonLake Immunotherapeutics investors who might have suffered losses during the stated period. By taking the steps outlined, they can seek to reclaim their investments amidst the ongoing allegations of misconduct by the company.